CTOs on the Move

Chimerix

www.chimerix.com

 
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.chimerix.com
  • 2505 Meridian Parkway Suite 100
    Durham, NC USA 27713
  • Phone: 919.806.1074

Executives

Name Title Contact Details
Roy Ware
Chief Manufacturing and Technology Officer Profile

Funding

Chimerix raised $100M on 01/21/2021

Similar Companies

Suncoast Pharmacy RX

Suncoast Pharmacy RX is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Saniona

Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical

Vitacorp International Inc

Vitacorp International Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Microline Surgical

Microline Surgical develops and manufactures high precision open and laparoscopic surgical instruments. Microline`s laparoscopic reposable instruments provide a cost-effective and eco-friendly solution for today`s OR. The MiFusion product line offers a broad spectrum of open and laparoscopic instruments used to seal and divide tissue utilizing proprietary Thermal Fusion technology.

Everest Medicines

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.